A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies
Published inLeukemia research, vol. 37, no. 9, p. 1100-1106
Publication date2013
Abstract
Keywords
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Hematologic Neoplasms/drug therapy/enzymology
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Prognosis
- Protein Kinase Inhibitors/pharmacokinetics/therapeutic use
- Remission Induction
- Tissue Distribution
Affiliation
Citation (ISO format)
GRAUX, Carlos et al. A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. In: Leukemia research, 2013, vol. 37, n° 9, p. 1100–1106. doi: 10.1016/j.leukres.2013.04.025
Main files (1)
Article (Published version)
Identifiers
- PID : unige:37151
- DOI : 10.1016/j.leukres.2013.04.025
- PMID : 23746966
ISSN of the journal0145-2126